Cargando…

Evaluation of Pembrolizumab Monotherapy Efficacy in Advanced Non-Small-Cell Lung Cancer by Serial Monitoring of Circulating Tumor DNA Using Next-Generation Sequencing

INTRODUCTION: Pembrolizumab is widely used in advanced non-small-cell lung cancer (NSCLC) patients with positive programmed death-ligand 1 (PD-L1). However, efficacy evaluation along treatment by serial monitoring of circulating tumor DNA (ctDNA) using next-generation sequencing remained to be well...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Buhai, Fan, Yaqin, Zhang, Liying, Liu, Liqin, Ma, Yutong, Ma, Xiaosong, Huang, Yuxiang, Wu, Yinxia, Liang, Yichen, Xu, Yang, Wu, Xue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859670/ https://www.ncbi.nlm.nih.gov/pubmed/35197718 http://dx.doi.org/10.1177/11795549221075326

Ejemplares similares

The Effect of Hippocampal Avoidance Whole Brain Radiotherapy on the Preservation of Long-Term Neurocognitive Function in Non-Small Cell Lung Cancer Patients With Brain Metastasis
por: Wang, Buhai, et al.
Publicado: (2021)

Evaluate the Prognosis of MYC/TP53 Comutation in Chinese Patients with EGFR-Positive Advanced NSCLC Using Next-Generation Sequencing: A Retrospective Study
por: Cao, Jin, et al.
Publicado: (2022)

Pulmonary pleomorphic carcinoma with pembrolizumab monotherapy
por: Chang, Hao‐Chun, et al.
Publicado: (2020)

Exceptional Regression of Malignant Pleural Mesothelioma with Pembrolizumab Monotherapy
por: Hearon, Bernard F., et al.
Publicado: (2020)

Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
por: Cristescu, Razvan, et al.
Publicado: (2022)

Construction of prognostic signature of breast cancer based on N7-Methylguanosine-Related LncRNAs and prediction of immune response
por: Cao, Jin, et al.
Publicado: (2022)

Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non‐small‐cell lung cancer: A multicenter retrospective trial
por: Matsumoto, Hiromi, et al.
Publicado: (2021)

A retrospective analysis of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for advanced or recurrent non‐small cell lung cancer
por: Isono, Taisuke, et al.
Publicado: (2021)

Efficacy of Pembrolizumab Monotherapy in Japanese Patients with Advanced Gastric or Gastroesophageal Junction Cancer
por: Muro, Kei, et al.
Publicado: (2023)

Next generation sequencing of HIV-1 protease in the PIVOT trial of protease inhibitor monotherapy
por: Dunn, David T., et al.
Publicado: (2018)

Serial monitoring of circulating tumour DNA on clinical outcome in myelodysplastic syndromes and acute myeloid leukaemia
por: Zhou, Xinping, et al.
Publicado: (2023)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%
por: Liu, Qiao, et al.
Publicado: (2022)

Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: A case series
por: Rose, Peter G., et al.
Publicado: (2023)

Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE‐100
por: Nishio, Shin, et al.
Publicado: (2020)

Complete remission of advanced lung adenocarcinoma with first-line pembrolizumab monotherapy: Two case reports
por: Gohara, Kazuki, et al.
Publicado: (2021)

Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?
por: Fiorelli, Alfonso, et al.
Publicado: (2019)

Next-generation sequencing–based monitoring of circulating tumor DNA reveals clonotypic heterogeneity in untreated PTCL
por: Miljkovic, Milos D., et al.
Publicado: (2021)

Editorial: Circulating molecular biomarkers: next-generation tools for monitoring minimal residual disease in cancer patients
por: Amoozgar, Zohreh, et al.
Publicado: (2023)

Integrated next-generation sequencing and comparative transcriptomic analysis of leaves provides novel insights into the ethylene pathway of Chrysanthemum morifolium in response to a Chinese isolate of chrysanthemum virus B
por: Zhong, Xueting, et al.
Publicado: (2022)

Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression
por: Takumida, Hiroshi, et al.
Publicado: (2021)

Next-Generation Sequencing Reveals the Progression of COVID-19
por: Chen, Xiaomin, et al.
Publicado: (2021)

Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma
por: Armand, Philippe, et al.
Publicado: (2023)

Monitoring of cancer patients via next‐generation sequencing of patient‐derived circulating tumor cells and tumor DNA
por: Onidani, Kaoru, et al.
Publicado: (2019)

Prometheus: a next-generation monitoring system
por: Reinartz, Fabian
Publicado: (2017)

Next‐generation conservation genetics and biodiversity monitoring
por: Hunter, Margaret E., et al.
Publicado: (2018)

Serial Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer to Predict the Therapeutic Response
por: Jia, Ning, et al.
Publicado: (2019)

Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer
por: Ngoi, N.Y.L., et al.
Publicado: (2018)

Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer
por: Noguchi, Susumu, et al.
Publicado: (2020)

Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab
por: Morita, Mitsunori, et al.
Publicado: (2020)

Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma
por: Robert, Caroline, et al.
Publicado: (2020)

Association of Performance Status With Survival in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy
por: Sehgal, Kartik, et al.
Publicado: (2021)

Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data
por: Terai, Hideki, et al.
Publicado: (2022)

Enfortumab vedotin and pembrolizumab as monotherapies and combination treatment in locally advanced or metastatic urothelial carcinoma: A narrative review
por: Bantounou, Maria A., et al.
Publicado: (2023)

Editorial: Circulating tumor DNA in cancer: a role as a response and monitoring “next-generation” biomarker in cancer therapy
por: Latifi-Navid, Saeid, et al.
Publicado: (2023)

SAMStat: monitoring biases in next generation sequencing data
por: Lassmann, Timo, et al.
Publicado: (2011)

The next generation of the ATLAS PanDA Monitoring System
por: Schovancova, J, et al.
Publicado: (2014)

The next generation of the ATLAS PanDA Monitoring System
por: Schovancova, J, et al.
Publicado: (2014)

Next-generation sequencing to monitor the spread of antimicrobial resistance
por: Otto, Michael
Publicado: (2017)

Advanced G‐CSF‐producing non‐small cell lung cancer‐not otherwise specified, with favourable response to pembrolizumab monotherapy
por: Matsui, Yohei, et al.
Publicado: (2020)

Real‐world outcomes of pembrolizumab monotherapy in non‐small cell lung cancer in Japan: A post‐marketing surveillance
por: Yamamoto, Nobuyuki, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_db0ccdoqriuphjp46fiest2eq0